1 Introduction

The immune system and its response to specific stimulation are extremely complex and precisely coordinated to protect the organism against pathogens and maintain homeostasis (Gunzer et al., 2012). However, a well-functioning immune system can be disrupted by multiple factors, such as inadequate nutrition (Salva et al., 2012), physical, psychological, and environmental stresses (Srikumar et al., 2006; Li et al., 2012) as well as oxidative stress (Wang J.X. et al., 2012). Both in vitro and in vivo studies supported the possibility that oxidative stress may be the major underlying cause of inflammatory and immune dysfunction (Sordillo and Aitken, 2009). In the case of impaired immunity, the individual suffers from increased susceptibility to a variety of illnesses (Dietert and Zelikoff, 2010; Morris et al., 2013). As the same with some chronic diseases, prevention is much more effective than treatment in immune suppression, and naturally occurring bioactive compounds derived from foodstuff have made a great contribution as a result of few side-effects and lower toxicity (Gil and Rueda, 2002; Zhang et al., 2013).

American ginseng (Panax quinquefolius L.), mainly grown in the United States and Canada, has occupied a prominent position in the enhancement of immune function (Yuan et al., 2010; Lemmon et al., 2012). In the past few decades, information on certain phytochemical features as well as chemical composition of gensenosides of American ginseng has been obtained (Qi et al., 2011). Also, pharmacological effects of American ginseng have been discovered. Ginseng saponins or ginsenosides are generally considered to be the major active constituents responsible for several pharmacological effects on cardiovascular disease (Li et al., 2010), endocrine disorders (Mucalo et al., 2013), cognitive function (Yuan et al., 1998), immune system, and cancer (Ichikawa et al., 2009; Kim, 2012; Barton et al., 2013). Because of its health benefits, particularly for its immune-enhancing effects, American ginseng has been made into a variety of products (Lesser and Shick, 1989), like capsule, liquid, and tablet products. However, the bottled beverage product may be more innovative and prospective compared with those product types.

Jujube (Zizyphus jujuba Mill.), a native fruit from China with a history of over 4000 years, has been widely used for the production of food itself, food additives, and flavorings on account of its particular nutritional value (Wang, 2011; Gao et al., 2013). As a result of developments in food research, much work has been done on jujube in recent decades and the nature of the polysaccharides present in jujube has been studied (Li et al., 2007; Zhao et al., 2008). On account of the abundance of polysaccharides in jujube, much attention has been directed to their extensive bioactivities in regard to immunomodulation (Zhang et al., 2013), anti-cancer (Plastina et al., 2012), anti-virus (Yen et al., 2014), and anti-oxidation properties (Shen et al., 2009). Although, jujube fruits can be made into paste, puree, syrup, and preparations to aid digestion and general health, deep-processing jujube products are still rare. Hence, it is worth studying the deep-processing jujube product to fulfill its maximizing value.

Previous reports suggested that mixtures of some bioactive components may exert a better effect compared with compounds used individually (Huang et al., 2007), which has motivated us to develop a new formula called Shenzao Cha (SZC), comprising American ginseng and Chinese jujube. The product was formulated with stable levels of total saponins and polysaccharides. The objective of the present study is to evaluate the immunomodulatory effect of SZC in a normal mouse model and to determine its antioxidant activity which might be relevant to immune enhancement.

2 Materials and methods

2.1 Materials

The American ginseng extract (Batch No. 20130103) was purchased from Ningbo Liwah Pharmaceutical Co., Ltd. (Ningbo, China), and Chinese jujube (Batch No. 130627) was purchased from East China Medicine Slice Co., Ltd. (Hangzhou, China). Yeast artificial chromosome-1 (YAC-1) cell, a murine lymphoma cell line, was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Fetal bovine serum was purchased from Zhejiang Tianhang Biological Technology Co., Ltd. (Hangzhou, China). Sheep red blood cells (SRBCs) were purchased from Sinri Bioengineering Co., Ltd. (Hangzhou, China). Nonidet P-40 (NP-40) was purchased from the Beyotime Institute of Biotechnology (Jiangsu, China). Trypan blue, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT), and concanavalin A (ConA) were purchased from Sigma (St. Louis, MO, USA). Roswell Park Memorial Institute 1640 (RPMI 1640) medium powder was purchased from Gibco (Grand Island, NY, USA). Ginsenoside Re, D-glucose, and isopropanol alcohol were purchased from Aladdin Industrial Co. (Shanghai, China). The 96-well round-bottom plates and 24-well plates were purchased from Corning Incorporated (New York, USA). Lactate dehydrogenase (LDH), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), and malondialdehyde (MDA) assay kits were purchased from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China).

2.2 Preparation of SZC

The SZC utilized in this study was developed from American ginseng (P. quinquefolius L.) and Chinese jujube (Z. jujuba Mill.). The American ginseng extract was dissolved in sterile water at a concentration of 0.26% (2.6 g/L). Jujube extract was prepared as follows: pulp was soaked in water at a ratio of 1:9 (w/w) for 1 h, hydrolyzed with pectinase for 4 h, then centrifuged at 3500 r/min for 15 min. Jujube and American ginseng extract solution were mixed at a ratio of 2:5 (v/v) to generate SZC. Finally, SZC was concentrated with a rotary evaporator under reduced pressure, and the concentrated solution was diluted with sterile water before use.

The total saponin content was determined following the method described by Xie et al. (2012) and ginsenoside Re was used as the standard. The amount of total polysaccharide in the sample was measured by the phenol-sulfuric acid colorimetric method (Wang D. et al., 2012) with glucose as a standard. The total saponin and polysaccharide contents in SZC were 7.84 and 16.82 mg/g raw material, respectively.

2.3 Animal experiments

Specific pathogen-free (SPF) ICR male mice ((20±2) g) were purchased from Shanghai Super-B&K Laboratory Animal Co., Ltd. (Shanghai, China) with a certificate No. SCXK (hu) 2013-0016. The mice were 6–7 weeks old at the start of the experiment. Mice were maintained in a temperature-controlled environment ((22±2) °C) with a 12 h/12 h light/dark cycle and given free access to water and food throughout the experiment. Any aspect of the work that involved experimental animals and their care was approved by the Committee on the Ethics of Animal Experiments of Zhejiang University in compliance with the National Institutes of Health Guide for Care and Use of Laboratory Animals.

After an acclimation period of 5 d, mice were randomly divided into four groups: control group (sterile water), SZC low-dose group (1.3 g raw material/kg body weight (BW)), SZC medium-dose group (2.6 g raw material/kg BW), and SZC high-dose group (5.2 g raw material/kg BW). All animals received intragastric administration once daily for four weeks. The body weight of mice was weighed at the start, in the middle, and at the end of the experiment.

2.4 Assay of spleen and thymus indices

Twenty-four hours after the last intragastric administration, animals were weighed and sacrificed. Spleen and thymus were then excised and weighed immediately, and the organ indices were calculated according to the following formula: W1/W0, where W1 is the weight of spleen or thymus, and W0 is the weight of the whole body.

2.5 Assay of serum hemolysis

After 24-d administration, each mouse was immunized by intraperitoneal injection of 0.2 ml suspension of 2% SRBCs. Four days later, blood from SRBC-immunized mice was collected and allowed to clot for 1–2 h. Serum was collected by centrifugation at 2000 r/min for 10 min. Assay of serum hemolysis was performed based on the method of Jiang et al. (2013). Briefly, the serum was diluted 500-fold with 0.9% (9 g/L) NaCl, and 1 ml of the diluted serum was mixed with 0.5 ml of 10% SRBCs (in 0.9% NaCl) and 1 ml of diluted guinea pig serum (1:10 (v/v) dilution). A blank control employing 0.9% NaCl solution instead of mouse serum was prepared synchronously. After incubation at 37 °C for 25 min, the reaction was terminated in an ice bath. The samples were centrifuged at 2000 r/min for 10 min at 4 °C, and supernatants were collected and mixed with 3 volumes of Drabkin’s reagent (1.0 g NaHCO3, 0.05 g KCN, 0.2 g K3Fe(CN)6, which was made up to 1 L with distilled water). At the same time, 0.25 ml SRBCs were blended with 4 ml Drabkin’s reagent as half hemolysis. The absorbance at 540 nm was read against the blank control. The hemolytic activity was calculated according to the following formula: hemolytic complement activity (HC50)=As/Ah×500, where As is the absorbance of test sample, and Ah is the absorbance of half hemolysis.

2.6 Assay of splenic lymphocyte proliferation

Splenocyte proliferation was measured by an MTT assay as described by Yang et al. (2009) with some modifications. Mice spleens were collected aseptically, homogenized gently in Hank’s solution with a pair of forceps, and passed through a 200-mesh fine steel sieve to obtain single-cell suspensions. After washing three times with Hank’s solution, the splenocytes were re-suspended in RPMI 1640 complete medium (RPMI 1640 medium with 10% fetal bovine serum, 100 U/ml streptomycin, and 100 U/ml penicillin) and adjusted to a concentration of 3×106 cells/ml. The cell numbers were counted by the trypan blue dye exclusion technique. Cell viability exceeded 95%. Then, cell suspensions were seeded into 24-well plates at 1 ml/well and cultured with 7.5 µg/ml ConA as stimulated samples or without ConA as non-stimulated samples. The plates were placed in a humid atmosphere with 5% CO2 at 37 °C. After 68 h of incubation, 50 µl of MTT solution (5 mg/ml) was added to each well for another 4-h incubation. Finally, 1 ml of isopropanol solution was added to fully solubilize the purple formazan crystals. The absorbance at 570 nm was read on an automated microplate reader.

The proliferation capacity of splenocytes was evaluated according to the following formula: Atest−Acontrol, where Atest is the absorbance of the stimulated sample, and Acontrol is the absorbance of the non-stimulated sample.

2.7 Assay of natural killer (NK) cell activity

The splenic natural killer cell activity was determined by its cytotoxicity against YAC-1 using a LDH release assay. The assay was performed as previously described with some modifications (Lv et al., 2013). In brief, splenocytes, acting as effector cells, were prepared as described, and YAC-1 cells were used as target cells in their log phase. Effector cells and target cells were mixed in a ratio of 50:1 in the 96-well round-bottom plates and co-incubated at 37 °C for 4 h in a humidified atmosphere of 5% CO2. After incubation, supernatants were collected for the detection of LDH activity, following the instructions of the LDH cytotoxicity detection kit. The percentage of cell-mediated cytotoxicity was calculated according to the following formula: NK cell activity (%)=(Af−An)/(Am−An)×100%, where Af is the LDH release due to the co-incubation of effector and target cells, An is the LDH release due to target cells incubated in the culture medium alone, and Am is the LDH release achieved by the addition of 1% NP-40 to target cells.

2.8 Biochemical assays

Twenty-four hours after the last sample administration, the serum, liver, spleen, and thymus were collected and stored at −80 °C for biochemical assay. The tissues were minced and homogenized in 10 volumes of cold 0.9% NaCl. Homogenates were centrifuged at 3000 r/min at 4 °C for 10 min. Protein contents in the homogenate supernatant were detected with the Coomassie brilliant blue method, while SOD, GSH-Px, and CAT activities and MDA content were all determined with commercial available assay kits following the manufacturers’ protocols.

SOD was determined according to the manufacturer’s protocol of SOD assay kit A001-1. Briefly, to achieve the optimal detection range, 20 µl of serum, 60 of 0.5% (5 g/L) liver homogenate, 100 µl of 2% (0.02 g/ml) spleen homogenate, and 100 µl of 2% (0.02 g/ml) thymus homogenate were prepared and then used for determination of SOD, respectively. The absorbance was measured at 550 nm on a microplate reader.

CAT in this study was measured according to the manufacturer’s protocol of CAT assay kit A007-1. Briefly, to achieve the optimal detection range, 20 µl of serum, 60 µl of 0.5% liver homogenate, 100 µl of 2% spleen homogenate, and 100 µl of 2% thymus homogenate were prepared for the determination of CAT, respectively. The absorbance of samples was detected at 405 nm at the end of reaction.

GSH-Px was determined based on the manufacturer’s protocol of GSH-Px assay kit A005. Briefly, to achieve the optimal detection range, 100 µl of 5-fold diluted serum, 200 µl of 0.25% liver homogenate, 200 µl of 1.5% spleen homogenate, and 200 µl of 5% thymus homogenate were prepared and then used for determination of GSH-Px, respectively. The absorbance of samples was detected at 412 nm at the end of reaction.

MDA was determined according to the manufacturer’s protocol of MDA assay kit A003-1. Briefly, to achieve the optimal detection range, 100 µl of serum, 200 of 10% liver homogenate, 200 µl of 10% spleen homogenate, and 200 µl of 10% thymus homogenate were prepared for the determination of MDA, respectively. The optical density (OD) of samples was measured at 450 nm.

2.9 Statistical analysis

All statistical analyses were performed with SPSS software for Windows, Version 17.0 (SPSS Inc., Chicago, Illinois, USA). Quantitative data were evaluated by one-way analysis of variance (ANOVA) followed by the Duncan’s test and expressed as the mean±standard error of the mean (SEM). P-values less than 0.05 were regarded as significant, while P-values less than 0.01 were considered to be extremely significant.

3 Results

3.1 Effects of SZC on body weight and spleen and thymus indices

In order to investigate the immunomodulatory effect of SZC, we first studied its protection against degenerative changes of the spleen and thymus. Table 1 demonstrated that all doses of SZC significantly increased the spleen and thymus indices in mice (P<0.01). In the high-dose group (5.2 g/kg), the spleen and thymus indices were approximately 1.6-and 1.9-fold higher than those in the control group, respectively.

Table 1 Effect of Shenzao Cha (SZC) on spleen and thymus indices
Full size table

Mice in different groups showed similar body weights at the same time point (Fig. 1), and no death or abnormality was observed throughout the experiment. These results indicated that SZC could markedly increase spleen and thymus indices without side-effects on the body weight of healthy ICR mice.

Fig. 1
figure 1

Effect of Shenzao Cha (SZC) on the body weights of mice during the experiment period

Data are expressed as mean±SEM (n=10)

Full size image

3.2 Effect of SZC on hemolytic activity

Hemolytic complement activity (HC50) was measured in SRBC-immunized mice to estimate the activity of serum hemolysis. As shown in Fig. 2a, HC50 values in the SZC administration groups were improved by 25.2% (1.3 g/kg), 13.3% (2.6 g/kg), and 13.8% (5.2 g/kg), respectively, compared with the control group. A significant difference was found between the low-dose (1.3 g/kg) group and control group (P<0.05). Thus, our results suggested that oral administration of SZC could play a positive role in humoral immunity.

Fig. 2
figure 2

Effect of Shenzao Cha (SZC) on the immune function in healthy ICR mice

(a) The formation of serum hemolysin; (b) The proliferation of splenic lymphocytes; (c) The activity of splenic NK cells. P<0.05 vs. control group. Data are expressed as mean±SEM (n=10)

Full size image

3.3 Effect of SZC on splenic lymphocyte proliferation

The effect of SZC on splenic lymphocyte proliferation was evaluated and the results are shown in Fig. 2b. In combination with T-cell mitogen (ConA, 7.5 µg/ml), SZC (1.3, 2.6, and 5.2 g/kg) administration markedly facilitated splenocyte proliferation. The largest lymphocyte proliferation, which was 1.4-fold higher than that in the control group, was observed in the high-dose (5.2 g/kg) group. The positive effect of SZC on T-lymphocyte proliferation implies that it has the potential to enhance cellular immunity.

3.4 Effect of SZC on splenic NK cell activity

The amount of LDH released into culture medium from damaged YAC-1 cells was chosen as an indicator of NK cell activity and determined by colorimetric assay (Fig. 2c). The NK cell activities in 2.6 and 5.2 g/kg SZC administration groups were significantly enhanced compared with the control group. In particular, 2.6 g/kg SZC administration increased the NK cell activity by 78.6% relative to the control.

3.5 Effects of SZC on the activities of SOD, GSH-Px, and CAT

To examine the effect of SZC on antioxidant activity in mice, the activities of antioxidant enzymes (SOD, GSH-Px, and CAT) in liver, spleen, thymus, and serum were measured.

As illustrated in Figs. 3a and 3b, SOD activities in liver and serum were noticeably raised (P<0.05) in all SZC-fed groups compared with controls. In thymus, the highest SOD activity was observed in the 1.3 g/kg administration group. Medium- (2.6 g/kg) and high-dose (5.2 g/kg) SZC also showed a minimal promoting effect (Fig. 3a). No significant difference was noticed in spleen, although the amounts in SZC administration groups were higher than those in controls (Fig. 3a).

Fig. 3
figure 3

Effects of Shenzao Cha (SZC) on the activities of SOD in liver, spleen, and thymus (a) and serum (b)

* P<0.05 vs. control group. Data are expressed as mean±SEM (n=8)

Full size image

For GSH-Px activities in liver and thymus, low-(1.3 g/kg) and medium-dose (2.6 g/kg) SZC both showed significant increases (P<0.05; Fig. 4a). SZC administration (1.3, 2.6, and 5.2 g/kg) all apparently raised the GSH-Px activity in serum compared with the sterile water control. In particular, 2.6 g/kg SZC administration increased the GSH-Px activity by 38.5% relative to controls (Fig. 4b). In the case of spleen, only low-dose (1.3 g/kg) SZC significantly improved the GSH-Px activity (Fig. 4a).

Fig. 4
figure 4

Effects of Shenzao Cha (SZC) on the activities of GSH-Px in liver, spleen, and thymus (a) and serum (b)

*P<0.05 vs. control group. Data are expressed as mean±SEM (n=8)

Full size image

As shown in Fig. 5a, the CAT activity in liver was significantly raised by SZC at all doses. Specifically, 1.3 g/kg SZC administration exhibited the greatest increase. SZC administration also improved the CAT activity in spleen by 13.0% (1.3 g/kg), 37.8% (2.6 g/kg), and 55.0% (5.2 g/kg), respectively, relative to sterile water controls. Apart from the low-dose group, SZC administration groups displayed a significant difference compared with the control group (Fig. 5a). The greatest CAT activity in serum was observed in the 2.6 g/kg SZC treatment group. Low- (1.3 g/kg) and high-dose (5.2 g/kg) also showed a significant promoting effect (Fig. 5b).

Fig. 5
figure 5

Effects of Shenzao Cha (SZC) on the activities of CAT in liver and spleen (a) and serum (b)

*P<0.05 vs. control group. Data are expressed as mean±SEM (n=8)

Full size image

3.6 Effects of SZC on the content of MDA

For liver, the contents of MDA in low- (1.3 g/kg) and medium-dose (2.6 g/kg) groups were significantly lower than those in controls (Fig. 6a). In serum, different doses of SZC significantly reduced the MDA levels by 25.5% (1.3 g/kg), 40.8% (2.6 g/kg), and 24.1% (5.2 g/kg), respectively, relative to controls (Fig. 6b). SZC reduced the MDA contents in spleen and thymus to some extent, but only the difference between the low-dose group (1.3 g/kg) and control was statistically significant (Fig. 6a).

Fig. 6
figure 6

Effects of Shenzao Cha (SZC) on the contents of MDA in liver, spleen, and thymus (a) and serum (b)

*P<0.05 vs. control group. Data are expressed as mean±SEM (n=8)

Full size image

4 Discussion

The immune system, consisting of innate and adaptive immunity, is the human’s ultimate defense against infection. Moreover, it has been considered as a health indicator and longevity predictor. However, stress, fatigue, and chemotherapy can result in undesirable immune suppression (Srikumar et al., 2006; Wang J.X. et al., 2012). In addition, immune cell functions, such as microbicidal activity of phagocytes and the lymphoproliferative response to mitogens, are related to the generation of reactive oxygen species (ROS) (Goldstone and Hunt, 1997). Excessive accumulation of ROS can exert negative effects on immune cells. For example, they can attract cellular components by oxidizing membrane lipid and accelerating glutathione (GSH) depletion (D’Autreaux and Toledano, 2007) eventually resulting in oxidative damage and immune depression. It is noticeable that food materials which are rich in bioactive constituents can neutralize ROS, protect organisms from oxidative damage, and enhance immune function. Among those food materials, American ginseng and Chinese jujube have attracted great attention in recent decades for their diverse pharmacological activities, particularly in immunomodulatory activity. According to published reports, American ginseng extract can modulate the immune function by promoting antibody formation, cytokine production, and NK cell activity, and preventing the effects of oxidative stress in mice (Yuan et al., 2010). Polysaccharides extracted from jujube can increase thymus and spleen indices as well as enhance the proliferation of splenocytes and peritoneal macrophages in mice (Zhao et al., 2006; Gao et al., 2013). Therefore, we developed a formula (SZC) containing American ginseng and Chinese jujube extracts, and, for the first time, explored its immunomodulatory properties. Our results demonstrated that oral administration of SZC could significantly enhance immune function in ICR mice.

Adaptive immunity responses, including humoral and cellular immunity, are mainly dependent on B- and T-lymphocytes, respectively. Antibody response following immunization with a foreign antigen is the first to be studied, but still remains as an important assay of immune function (LeMaoult et al., 1997). When mice are immunized with SRBC, B-lymphocytes would secrete hemolysin, whose content in serum is used to evaluate the functional status of humoral immunity (Yang et al., 2009). T-lymphocytes could eliminate the target cells directly as well as release various cytokines, and their proliferation is crucial for the activation cascade of both humoral and cellular immune responses (Chen et al., 2012). In the present study, serum hemolysin formation and T-lymphocyte proliferation with its mitogen ConA were determined to elucidate the effect of SZC on adaptive immunity. HC50 in SZC administration groups was significantly or numerically higher than that in controls (Fig. 2a), and T-lymphocyte proliferation was also markedly accelerated (Fig. 2b); this meant that both humoral and cellular immunities were improved. The response to T-dependent antigen SRBC requires the co-operation of macrophages and T- and B-lymphocytes, which might explain why SZC did not show an equivalent effect on HC50 and T-lymphocyte proliferation. As in several other studies (Zhu et al., 2007; Lv et al., 2013), the low-dose was found to be the most effective in serum hemolysin formation. As macrophages play an important role in the processing and presenting of antigen to T- and B-lymphocytes, suggesting that a dose increase might have induced down-regulation of the function of macrophages. In addition, SZC significantly increased the indices of spleen and thymus, in which lymphocytes reside and undergo differentiation and maturation. Based on these results, we proposed that SZC can markedly improve the adaptive immunity of ICR mice after a 4-week administration.

Besides the adaptive immunity, innate immunity is also critical to the host immune system. NK cells are large granular lymphocytes derived from bone marrow and reside primarily in the spleen (Durairaj et al., 2013). They are characterized by their ability to spontaneously kill pathogen-infected cells and tumor cells, thus acting as major components of innate immunity (Wu et al., 2007). The activity of NK cells is controlled by interaction between activating and inhibitory receptors expressed on NK cells and ligands presented on target cell surfaces (Tian et al., 2012). In the present study, the YAC-1 cell was utilized as the target cell and splenic NK cells were collected to assess the effect of SZC on NK cell activity. An apparent difference was observed between SZC-fed and control groups, which represented a more vigorous cytolytic activity of NK cells toward the target cells as well as a promotion of innate immunity by SZC administration. A similar phenomenon was also observed by See et al. (1997). Because NK cells not only recognize and kill tumor or virus-infected cells, but also regulate the activities of other immune cells via the secretion of cytokines and chemokines, such as interferon (IFN)-γ and tumor necrosis factor (TNF)-α (Oshimi, 2007). Hence, further studies detecting these cytokines by ELISA are needed to understand more comprehensively the influence of SZC on NK cells.

Growing evidence implies oxidative stress as a mechanism contributing to the decline in physiological functions of the immune system (Sordillo and Aitken, 2009). Cells and organisms in the immune system are more susceptible to oxidative stress, as immune responses generally lead to the generation of ROS, especially in the “respiratory burst” stimulated by neutrophils and macrophages (Knight, 2000). Antioxidants play a pivotal role in scavenging the ROS, thereby protecting the tissues from oxidative damage and preserving adequate function. Likewise, the beneficial effects of antioxidants on immune functions in vitro and in vivo have been frequently observed. For example, Kim et al. (2012) reported that depletion of ascorbic acid could impair NK cell activity. Additionally, de la Fuente and Victor (2000) suggested that N-acetylcysteine and vitamin E could balance altered immune functions to optimum effect. In addition, results presented in this study indicated that the immunomodulatory effect of SZC might be due to antioxidant activities.

In order to avoid oxidative stress, diverse anti-oxidant defense mechanisms have been developed that can effectively scavenge ROS before causing oxidation to macromolecules (Sordillo and Aitken, 2009). Antioxidant enzymes are among the most efficient defense mechanisms, and the three primary enzymes involved in neutralizing ROS are SOD, CAT, and GSH-Px. MDA is one of the final decomposition products of lipid peroxidation (LPO), and reflects the extent of the injury suffered by cellular membranes (Fan et al., 2014). In the present study, SZC generated a significant increase of antioxidant enzyme activities in liver and serum (SOD, CAT, GSH-Px), as well as an evident decrease of MDA content. The oxidative stresses in spleen and thymus were also reduced to a certain extent. The results are similar to the previous studies in which antioxidant activities of American ginseng and Chinese jujube were observed (Kim et al., 2007; Shen et al., 2009; Wang J.X. et al., 2012). These findings suggested that the antioxidant activities of SZC might partially contribute to the immunomodulatory function.

5 Conclusions

In summary, SZC exhibited dramatic immunomodulatory effects in ICR mice through intragastric administration. Moreover, its antioxidant activities were also observed, which might contribute to the immune enhancement. Therefore, our findings provide experimental evidence that SZC can be used daily to improve one’s health and immune function efficiently. We have not performed any metabolic studies on SZC, owing to complexity of metabolism in humans. Further studies are required to develop an effective administration of SZC, and to investigate the mechanism underlying the immunomodulation before administration in humans is performed.

Compliance with ethics guidelines

Zhuo-ping YU, Dong-dong XU, Lai-feng LU, Xiao-dong ZHENG, and Wei CHEN declare that they have no conflict of interest.

All institutional and national guidelines for the care and use of laboratory animals were followed.